NONINVASIVE ASSESMENT OF LIVER FIBROSIS, SEROLOGICAL MARKERS

Open Access Open Access
Restricted Access Subscription Access

Abstract


There is an increased interest in determining liver fibrosis using biological markers in recent years. Serological markers of liver fibrosis are an attractive alternative to liver biopsy because of price that suits both the patient and clinician. In addition to that this method is almost non-invasive to assess liver fibrosis with a small number of diagnostic errors, can be used in the dynamics which allows to monitor the level of fibrosis.

P N Fedorov

Pavlov First Saint-Petersburg State Medical University; Center for Control of AIDS and Infectious Diseases

Email: efv@inbox.ru
St.-Petersburg, Russia

N A Belyakov

Pavlov First Saint-Petersburg State Medical University; Center for Control of AIDS and Infectious Diseases

St.-Petersburg, Russia

  1. Park S. H., Kim C. H., Kim D. J. et al. Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B // J. Clin. Gastroenterol.- 2011.- Vol. 45, № 4.- P. 361-365.
  2. Grigorescu M. Noninvasive Biochemical Markers of Liver Fibrosis // J Gastrointestin. Liver Dis.- 2006.- Vol. 15, № 2.- P. 149-159.
  3. Gressner O. A., Weiskirchen R., Gressner A. M. et al. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver dependent malfunction tests // Clin. Chim. Acta.- 2007.- Vol. 381.- P. 107-113.
  4. Veidal S.S., Vassiliadis E., Bay-Jensen A.C. et al. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats // Fibrogenesis Tissue Repair.- 2010.- Vol. 3, № 1.- P. 5.
  5. Lieber C.S., Weiss D.G., Paronetto F. Veterans Affairs Cooperative Study 391 Group. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease // Alcohol. Clin. Exp. Res.- 2008.- Vol. 32, № 6.- P. 1031-1039.
  6. Jarcuska P., Janicko M., Veseliny E. et al. Circulating markers of liver fibrosis progression // Clin. Chimica Acta.- 2010.- Vol. 411, № 15-16.- P. 1009-1017.
  7. Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells // Journal of Signal Transduction.- 2010.- Vol. 2010.- P. 1-7.
  8. Takahara T., Furui K., Yata Y. et al. Dual expression of matrix protease-2 and membrane type I-matrix proteinase in fibrotic human livers // Hepatology.- 1997.- Vol. 26.- P. 1521-1529.
  9. Walsh K. M., Timms P., Campbell S. et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as non invasive markers of liver disease inchronic hepatitis C: comparison using ROC analysis // Dig Dis Sci.- 1999.- Vol. 44.- P. 624-630.
  10. Murawaki Y., Ikuta Y., Idobe Y. et al. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis // J. Gastroenterol. Hepatol.- 1999.- Vol. 14.- P. 138-145.
  11. Hayasaka A., Suzuki N., Fujimoto N. et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma // Hepatology.- 1996.- Vol. 24.- P 1058-1062.
  12. Badra G., Lotfy M., El-Refaie A. et al. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients // Acta Microbiol. Immunol. Hung.- 2010.- Vol. 57, № 1.- P. 29-42.
  13. Bataller R., Brenner D. A. Liver Fibrosis // The Journal of Clinical Investigation.- 2005.- Vol. 115.- № 2.- P. 209-218.
  14. Manning D. S., Afdhal N. H. et al. Diagnosis and quantitation of fibrosis // Gastroenterology.- 2008.- Vol. 134, № 6.- P. 1670-1681.
  15. Kanzler S., Baumann M., Schirmacher P. et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta // J. Viral Hepat.- 2001.- Vol. 8, № 6.- P. 430-437.
  16. Lydatakis H., Hager I. P., Kostadelou E. et al. Non-invasive markers to predict the liver fibrosis in non alcoholic fatty liver disease // Liver Int.- 2006.- Vol. 26.- P. 864-871.
  17. Tran A., Benzaken S., Saint-Paul M. C. et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease // Eur. J. Gastroenterol. Hepatol.- 2000.- Vol. 12, № 9.- P. 989-993.
  18. Kropf J., Gressner A. M., Negwer A. et al. Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases // Clinical Chemistry.- 1988.- Vol. 34.- P. 2026-2030.
  19. Korner T., Kropf J., Gressner A. M. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value // J. Hepatol.- 1996.- Vol. 25.- P. 684-688.
  20. Gressner O. A., Gressner A. M. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases // Liver Int.- 2008.- Vol. 28.- P. 1065-1079.
  21. Camps J., Marsillach J., Joven J. Measurement of serum paraoxonase-1 activity in the evaluation of liver function // World J. Gastroenterol.- 2009.- Vol. 15, № 16.- P. 1929-1933.
  22. Ferre N., Camps J., Prats E. et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage // Clin. Chem.- 2002.- Vol. 48, № 2.- P. 261-268.
  23. Molleken C., Sitek B., Henkel C. et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis // Hepatology.- 2009.- Vol. 49, № 4.- P. 1257-1266.
  24. Haukeland J. W., Schreiner L. T., Lorgen I. et al. AST/ALT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis // Scand. J. Gastroenterol.- 2008.- Vol. 43, № 10.- P. 1241-1248.
  25. Giboney P. T. Mildly elevated liver transaminase levelsin the asymptomatic patient // Am. Fam. Physician.- 2005.- Vol. 71, № 6.- P. 1105-1110.
  26. Nguyen-Khac E., Chatelain D., Tramier B. et al. Assessment of asymptomatic liver fibrosis in alcoholic patients using FibroScan: prospective comparison with seven non-invasive laboratory tests // Aliment. Pharmacol. Ther.- 2008.- Vol. 28, № 10.- P.1188-1198.
  27. Lu L. G., Zeng M. D., Mao Y. M. et al. Relationship between clinical and pathologic findings in patients with chronic liver diseases // World J. Gastroenterol.- 2003.- Vol. 9, № 12.- P. 2796-2800.
  28. DallaPiazza M., Amorosa V. K., Localio R. et al. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients // BMC Infect. Dis.- 2010.- Vol. 10, № 116.
  29. Lin Z. H., Xin Y. N., Dong Q. J. et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis // Hepatology.- 2011.- Vol. 53, № 3.- P. 726-736.
  30. Rossi E., Adams L. A., Bulsara M. et al. Assessing liver fibrosis with serum marker models // Clin. Biochem. Rev.- 2007.- Vol. 28, № 1.- P. 3-10.
  31. Guechot J., Lasnier E., Sturm N. et al. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort // Clin. Chim. Acta.- 2010.- Vol. 411, № 1-2.- P. 86-91.
  32. Sterling R. K., Lissen E., Clumeck N. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/ВГС coinfection // Hepatology.- 2006.- Vol. 43.- P. 1317-1325.
  33. Vallet-Pichard A., Mallet V., Nalpas B. et al. FIB-4: An inexpensive and accurate marker of fibrosis in ВГС infection, comparison with liver biopsy and fibrotest // Hepatology.- 2007.- Vol. 46, № 1.- P. 32-36.
  34. Kelleher T. B., Mehta S. H., Bhaskar R. et al. Prediction of hepatic fibrosis in HIV/ВГС co-infected patients using serum fibrosis markers: The SHASTA index // J. Hepatology.- 2005.- Vol. 43, № 1.- P. 78-84.
  35. Braden B., Faust D., Sarrazin U. et al. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection // Aliment. Pharmacol. Ther.- 2005.- Vol. 21, № 2.- P. 179-185.
  36. Lalazar G., Pappo O., Hershcovici T. et al. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic ВГС infection and normal ALT // J. Viral. Hepat.- 2008.- Vol. 15, № 10.- P. 716-728.
  37. Patel K., Gordon S.C., Jacobson I. et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate to advanced liver fibrosis in chronic hepatitis C patients // J. Hepatol.- 2004.- Vol. 41.- P. 935-942.
  38. Patel K., Nelson D. R., Rockey D. C. et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C // Clin. Gastroenterol. Hepatol.- 2008.- Vol. 6, № 2.- P. 242-247.
  39. Rossi E., Adams L., Prins A. et al. FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients // Validation of the Clin. Chem.- 2003.- Vol. 49, № 3.- P. 450-454.
  40. Imbert-Bismut F., Messous D., Thibault V. et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in heALThy blood donors // Clin. Chem. Lab. Med.- 2004.- Vol. 42, № 3.- P. 323-333.
  41. Friedrich-Rust M., Rosenberg W., Parkes J. et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis // BMC Gastroenterology.- 2010.- Vol. 10.- P. 103.
  42. Koda M., Matunaga Y., Kawakami M., Kishimoto Y. et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C // Hepatology.- 2007.- Vol. 45.- P. 297-306.
  43. Sebastiani G., Vario A., Guido M. et al. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases // J. Viral. Hepat.- 2008.- Vol. 15, № 3.- P. 212-218.
  44. Pilette C., Rousselet M. C., Bedossa P. et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers // J. Hepatol.- 1998.- Vol. 28.- P. 439-446.
  45. Cales P., Boursier J., Oberti F. et al. FibroMeters: a family of blood tests for liver fibrosis // Gastroenterol. Clin. Biol.- 2008.- Vol. 32, № 6.- P. 40-51.
  46. Angulo P., Hui J. M., Marchesini G. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD // Hepatology.- 2007.- Vol. 45.- P. 846-854.
  47. Rosenberg W.M., Voelker M., Thiel R. et al. Serum markers detect the presence of liver fibrosis: a cohort study // Gastroenterology.- 2004.- Vol. 127.- P. 1704-1713.
  48. Guha I. N., Parkes J., Roderick P. et al. Non-invasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European Liver Fibrosis panel and exploring simple markers // Hepatology.- 2008.- Vol. 47, № 2.- P. 455-460.
  49. Callewaert N., Vlierberghe H. V., Hecke A. V. et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics // Nature Medicine.- 2004.- Vol. 10.- P. 429-434.
  50. Blomme B., Van Steenkiste C., Callewaert N. et al. Alteration of protein glycosylation in liver diseases // J. Hepatol.- 2009.- Vol. 50, № 3.- P. 592-603.
  51. Younossi Z.M., Baranova A., Stepanova M. et al. Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis // J. Proteom. Res.- 2010.- Vol. 9.- № 6.- P. 3218-3224.
  52. Sebastiani G., Vario A., Guido M. et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C // J. Hepatol.- 2006.- Vol. 44, № 4.- P. 686-693.
  53. Sebastiani G., Halfon P., Castera L. et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C // Hepatology.- 2009.- Vol. 49, № 6.- P. 1821-1827.
  54. Ibanez J. G., Perez M., Lamas J. L. et al. Grade of consistency existing in the grade of hepatic fibrosis calculated with the APRI and FORNS biochemistry indexes and transient elastography (Fibroscan) in patients coinfected with HIV-ВГС // Rev. Clin. Esp.- 2010.- Vol. 210, № 7.- P. 317-322.

Views

Abstract - 17

PDF (Russian) - 0

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2014 Fedorov P.N., Belyakov N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.